Endocrine therapy serves as a cornerstone treatment approach for systemic treatment in HR+/HER2− breast cancer, followed by aromatase inhibitors, selective estrogen receptor degraders, CDK4/6 inhibitors (CDK4/6i), and selective estrogen receptor modulators, which have also demonstrated clinical benefits [4]. The gene discussed is ESR1; the disease is breast carcinoma.